Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.

Future oncology (London, England) - 1 Dec 2023

Akbıyık Ilgın, Ürün Yüksel

Abstract excerpt

The treatment landscape for castration-resistant prostate cancer (mCRPC) is undergoing significant advancements, particularly with the emergence of poly(ADP-ribose) polymerase inhibitors and their recent US FDA authorizations. The combination of olaparib with abiraterone and prednisone/prednisolone has gained approval for mCRPC patients harboring confirmed BRCA mutations. Subsequently, talazoparib in combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Mutation
Share to Poly(ADP-ribose) Polymerase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Prostatic Neoplasms, Castration-Resistant

Source

Identifiers

PMID: 38073492
DOI: 10.2217/fon-2023-0550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.PMID 38073492Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

PARP inhibitors in advanced prostate cancer: when to use them?Semantic proximity Read ↗

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?Semantic proximity Read ↗

Emerging Biomarker-Guided Therapies in Prostate CancerSemantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.